Platelet gpiiia p1 a1 and p1 a2 epitopes, their preparation and use
CA 2125486 C · Owner: Ginsberg, Mark H. · Inventors: Bowditch, Ronald D.; Ginsberg, Mark H.; Mcmillan, Robert
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Polypeptides and fusion polypeptides that immunologically mimic the native P1A1 and P1A2 determinants of platelet protein GPIIIa are disclosed. Also disclosed are DNA segments and recombinant DNA molecules that encode those polypeptides and fusion polypeptides and methods for expressing and using those determinants. Antibodies that immunoreact with one determinant or the other, but not both are also disclosed as are methods , of preparing and using those antibodies.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 24, 1992 and granted September 7, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 24, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 24, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.